Drug Shortage Report for TEVA-OLANZAPINE
Report ID | 163933 |
Drug Identification Number | 02276720 |
Brand name | TEVA-OLANZAPINE |
Common or Proper name | TEVA-OLANZAPINE 5MG TABLETS |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | OLANZAPINE |
Strength(s) | 5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | N05AH |
ATC description | ANTIPSYCHOTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-06-30 |
Estimated end date | 2022-08-30 |
Actual end date | 2022-08-19 |
Shortage status | Resolved |
Updated date | 2022-08-20 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-08-20 | English | Compare |
v5 | 2022-08-18 | French | Compare |
v4 | 2022-08-18 | English | Compare |
v3 | 2022-07-01 | English | Compare |
v2 | 2022-06-30 | French | Compare |
v1 | 2022-06-30 | English | Compare |
Showing 1 to 6 of 6